RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%

Recordati delivered solid first-half 2026 results with net revenue growth of 6.6% (9.1% at constant exchange rates), demonstrating consistent operational momentum across its pharmaceutical portfolio. The 8.8% EBITDA expansion to €540.2 million and margin maintenance at 38.3% reflect effective cost management and pricing resilience despite persistent currency headwinds of €34.5 million. Adjusted net income growth of 6.7% underscores earnings quality.

The company's free cash flow generation strengthened materially, rising €42.6 million year-over-year to €299.4 million, signaling improved working capital efficiency and capital deployment capability. Notably, reported net income jumped 24.8%, though this includes non-recurring benefits. Net debt remains disciplined at €1,917.1 million, maintaining leverage below 1.9x EBITDA, which preserves financial flexibility for strategic investment or shareholder returns.

The reaffirmation of FY 2026 guidance suggests management confidence in maintaining growth trajectory despite macroeconomic uncertainty. Geographic diversification and the group's specialty pharma positioning provide buffer against regional demand volatility. However, FX sensitivity remains a material headwind; further euro strength could compress reported metrics.

Sector implication: Results reinforce the defensive characteristics of pharmaceutical equities in uncertain markets. Recordati's mid-single-digit organic growth, combined with stable margins and cash generation, positions it as a relatively stable income play within Health Care, though growth remains modest relative to biotech peers.